ICH Harmonised Tripartite Guideline

Evaluation and Recommendation of Pharmacopoeial Texts for Use in the ICH Regions on Bulk Density and Tapped Density of Powders General Chapter Q4B Annex 13

Current Step 4 version dated 7 June 2012

This Guideline has been developed by the appropriate ICH Expert Working Group and has been subject to consultation by the regulatory parties, in accordance with the ICH Process. At Step 4 of the Process the final draft is recommended for adoption to the regulatory bodies of the European Union, Japan and USA.
# Q4B Annex 13
## Document History

<table>
<thead>
<tr>
<th>Code</th>
<th>History</th>
<th>Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Q4B Annex 13</td>
<td>Approval by the Steering Committee under <em>Step 2</em> and release for public consultation.</td>
<td>9 June 2010</td>
</tr>
</tbody>
</table>

**Current *Step 4* version**

<table>
<thead>
<tr>
<th>Code</th>
<th>History</th>
<th>Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Q4B Annex 13</td>
<td>Approval by the Steering Committee under <em>Step 4</em> and recommendation for adoption to the three ICH regulatory bodies.</td>
<td>7 June 2012</td>
</tr>
</tbody>
</table>
EVALUATION AND RECOMMENDATION OF PHARMACOPOEIAL TEXTS FOR USE IN THE ICH REGIONS ON BULK DENSITY AND TAPPED DENSITY OF POWDERS GENERAL CHAPTER Q4B ANNEX 13

ICH Harmonised Tripartite Guideline
Having reached Step 4 of the ICH Process at the ICH Steering Committee meeting on 7 June 2012, this guideline is recommended for adoption to the three regulatory parties to ICH

TABLE OF CONTENTS

1. INTRODUCTION ........................................................................................................... 1
2. Q4B OUTCOME ........................................................................................................... 1
   2.1 Analytical Procedures ......................................................................................... 1
   2.2 Acceptance Criteria ......................................................................................... 1
3. TIMING OF ANNEX IMPLEMENTATION ................................................................. 1
4. CONSIDERATIONS FOR IMPLEMENTATION ....................................................... 1
   4.1 General Consideration ...................................................................................... 1
   4.2 FDA Consideration ........................................................................................... 1
   4.3 EU Consideration .............................................................................................. 2
   4.4 MHLW Consideration ....................................................................................... 2
   4.5 Health Canada Consideration .......................................................................... 2
5. REFERENCES USED FOR THE Q4B EVALUATION ............................................... 2
EVALUATION AND RECOMMENDATION OF PHARMACOPOEIAL TEXTS FOR USE IN THE ICH REGIONS ON BULK DENSITY AND TAPPED DENSITY OF POWDERS GENERAL CHAPTER Q4B ANNEX 13

1. INTRODUCTION
This annex is the result of the Q4B process for the Bulk Density and Tapped Density of Powders General Chapter.
The proposed texts were submitted by the Pharmacopoeial Discussion Group (PDG).

2. Q4B OUTCOME

2.1 Analytical Procedures
The ICH Steering Committee, based on the evaluation by the Q4B Expert Working Group (EWG), recommends that the analytical procedures described in the official pharmacopoeial texts, Ph.Eur. 2.9.34. Bulk Density and Tapped Density of Powders, JP 3.01 Determination of Bulk and Tapped Densities, and USP General Chapter <616> Bulk Density and Tapped Density of Powders, can be used as interchangeable in the ICH regions.

2.2 Acceptance Criteria
The texts evaluated did not contain acceptance criteria.

3. TIMING OF ANNEX IMPLEMENTATION
When this annex is implemented (incorporated into the regulatory process at ICH Step 5) in a region, it can be used in that region. Timing might differ for each region.

4. CONSIDERATIONS FOR IMPLEMENTATION

4.1 General Consideration
When sponsors or manufacturers change their existing methods to the implemented Q4B-evaluated pharmacopoeial texts that are referenced in Section 2.1 of this annex, any change notification, variation, and/or prior approval procedures should be handled in accordance with established regional regulatory mechanisms pertaining to compendial changes.

4.2 FDA Consideration
Based on the recommendation above, and with reference to the conditions set forth in this annex, the pharmacopoeial texts referenced in Section 2.1 of this annex can be considered interchangeable. However, FDA might request that a company demonstrate that the chosen method is acceptable and suitable for a specific material or product, irrespective of the origin of the method.
4.3 EU Consideration

For the European Union, regulatory authorities can accept the reference in a marketing authorisation application, renewal or variation application citing the use of the corresponding text from another pharmacopoeia as referenced in Section 2.1, in accordance with the conditions set out in this annex, as fulfilling the requirements for compliance with the Ph. Eur. Chapter 2.9.34. on the basis of the declaration of interchangeability made above.

4.4 MHLW Consideration

The pharmacopoeial texts referenced in Section 2.1 of this annex can be used as interchangeable in accordance with the conditions set out in this annex. Details of implementation requirements will be provided in the notification by MHLW when this annex is implemented.

4.5 Health Canada Consideration

In Canada any of the texts cited in Section 2.1 of this annex and used in accordance with the conditions set out in this annex can be considered interchangeable.

5. REFERENCES USED FOR THE Q4B EVALUATION


5.2 The pharmacopoeial references for the Bulk Density and Tapped Density of Powders General Chapter for this annex are:


5.2.3 United States Pharmacopeia (USP): <616> Bulk Density and Tapped Density of Powders, USP 34, 2nd Supplement official December 1, 2011).